Skip to Content

European committee: Regulators should deny Merck’s Lagevrio

KIFI

By TOM MURPHY
AP Health Writer

A European medical committee recommends rejection of Merck’s COVID-19 treatment, Lagevrio, casting fresh doubt on a pill that also stirs concern among U.S. regulators. A European Medicines Agency committee says marketing authorization for the antiviral pill for use in the European Union should be refused. A statement from the agency says a committee that has been reviewing Merck’s application for more than a year concluded that the drug’s clinical benefit could not be demonstrated. Merck said Friday that it plans to appeal the recommendation, which came from the Committee for Medicinal Products for Human Use.

Article Topic Follows: AP National Business

Jump to comments ↓

Author Profile Photo

Associated Press

BE PART OF THE CONVERSATION

KIFI Local News 8 is committed to providing a forum for civil and constructive conversation.

Please keep your comments respectful and relevant. You can review our Community Guidelines by clicking here

If you would like to share a story idea, please submit it here.

Skip to content